Publication date: Oct 09, 2019
Recent evidence suggests that immunotherapy efficacy in melanoma is modulated by gut microbiota. Few studies have examined this phenomenon in humans, and none have incorporated metatranscriptomics, important for determining expression of metagenomic functions in the microbial community.
In melanoma patients undergoing immunotherapy, gut microbiome was characterized in pre-treatment stool using 16S rRNA gene and shotgun metagenome sequencing (n = 27). Transcriptional expression of metagenomic pathways was confirmed with metatranscriptome sequencing in a subset of 17. We examined associations of taxa and metagenomic pathways with progression-free survival (PFS) using 500 cD7 10-fold cross-validated elastic-net penalized Cox regression.
Higher microbial community richness was associated with longer PFS in 16S and shotgun data (p
Open Access PDF
Peters, B.A., Wilson, M., Moran, U., Pavlick, A., Izsak, A., Wechter, T., Weber, J.S., , Osman, and Ahn, J. Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients. 24420. 2019 Genome Med (11):1.
- Gastrointestinal tract dysbiosis enhances distal tumor progression through suppression of leukocyte trafficking.
- B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma.